UK markets close in 4 hours 34 minutes

Valneva SE (0OB3.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.52+0.40 (+3.90%)
As of 11:29AM BST. Market open.
Full screen
Previous close10.13
Open10.28
Bid0.00 x 0
Ask0.00 x 0
Day's range10.28 - 10.64
52-week range10.28 - 10.64
Volume5,465
Avg. volumeN/A
Market cap9.446M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-0.71
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

    Saint-Herblain (France), August 15, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an At-the-Market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $75.0 million of American Depositar

  • Reuters

    Valneva cuts full-year outlook on lower COVID-19 vaccine sales

    The European Commission in July slashed its order for VLA2001 to just 1.25 million doses from a previously targeted 60 million, pointing to European countries being well supplied with other vaccines and a slowdown in vaccination programmes. In February, Valneva had said it expected 350-500 million euros in COVID-19 vaccine sales. In the six months to June, the shot's sales brought in 3.8 million euros and the firm recognised writedowns of 100.6 million linked to the production inventory it bought to meet the initial purchase agreement with the European Commission, and subsequent halt of production.

  • Globe Newswire

    Valneva Reports H1 2022 Results and Provides Corporate Updates

    Excellent progress on late-stage clinical programs Lyme Disease Vaccine Candidate VLA15 Phase 3 study initiated in August 20221Further positive Phase 2 results reported, including first pediatric data2 Single-Shot Chikungunya Vaccine Candidate VLA1553 Initiation of rolling submission for Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) imminentFinal positive pivotal Phase 3 results reported3Final positive lot-to-lot consistency Phase 3 results reported4 Four m